COMy 2017 | The ongoing debate for treating multiple myeloma
Xavier Leleu
• 21 Apr 2017
Xavier Leleu, MD, PhD of Poitiers University Hospital, Poitiers, France discusses the factors that influence the choice of continuous therapy versus fixed duration therapy in patients with multiple myeloma (MM). Dr Leleu explores the feasibility of continuous treatment, with the goal of striking a balance between optimizing the patient’s quality of life, cost efficiency, the development of resistance and evidence-based practice. He also discusses triplet vs doublet regimens and the need to target treatment choices towards specific patient groups whilst prioritizing the patient’s well-being. Recorded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
